Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation

LAUR Repository

Show simple item record

dc.contributor.author Abdalla, Eddie
dc.contributor.author Wayne, Jeffrey
dc.contributor.author Wolff, Edward
dc.contributor.author Crane, Christopher
dc.contributor.author Pisters, Peter
dc.contributor.author Evans, Douglas
dc.date.accessioned 2015-11-10T10:07:39Z
dc.date.available 2015-11-10T10:07:39Z
dc.date.copyright 2002
dc.date.issued 2015-11-10
dc.identifier.issn 1083-7159 en_US
dc.identifier.uri http://hdl.handle.net/10725/2512
dc.description.abstract Pancreatic adenocarcinoma is the fifth leading cause of cancer-related death in the U.S. In spite of advancements in surgical treatment, nearly 80% of patients thought to have localized pancreatic cancer die of recurrent or metastatic disease when treated with surgery alone. Therefore, efforts to alter the patterns of recurrence and improve survival for patients with pancreatic cancer currently focus on the delivery of systemic therapy and irradiation before or after surgery. Postoperative adjuvant therapy appears to improve median survival. However, more than one-fourth of patients do not complete planned adjuvant therapy due to surgical complications or a delay in postoperative recovery of performance status. Utilizing a preoperative (neoadjuvant) approach, overall treatment time is reduced, a greater proportion of patients receive all components of therapy, and patients with rapidly progressive disease are spared the side effects of surgery as metastatic disease may be found at restaging following chemoradiation (prior to surgery). This paper examines the factors pertinent to clinical trial design for resectable pancreatic cancer, and carefully reviews the existing data supporting adjuvant and neoadjuvant therapy for potentially resectable disease. en_US
dc.language.iso en en_US
dc.title Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal The Oncologist en_US
dc.journal.volume 7 en_US
dc.journal.issue 1 en_US
dc.article.pages 34-45 en_US
dc.keywords Adenocarcinoma en_US
dc.keywords Pancreas en_US
dc.keywords Pancreaticoduodenectomy en_US
dc.keywords Antineoplastic agents en_US
dc.keywords Chemotherapy en_US
dc.keywords Radiotherapy en_US
dc.keywords Adjuvant therapy en_US
dc.keywords Neoadjuvant therapy en_US
dc.identifier.doi http://dx.doi.org/10.1634/theoncologist.7-1-34 en_US
dc.identifier.ctation Wayne, J. D., Abdalla, E. K., Wolff, R. A., Crane, C. H., Pisters, P. W., & Evans, D. B. (2002). Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. The Oncologist, 7(1), 34-45. en_US
dc.author.email eddie.abdalla@lau.edu.lb

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account